AND FAR MORE THAN MSB STATED .. there are 12 mill.in India with arthritic conditons and China ?? The figures below appear to be for the U.S ....
Rheumatoid Arthritis Comes with a Heavy Cost to Patients, Economy
Written by Ashley Boynes-Shuck | Published on April 8, 2016
People with RA pay heavily for their medications, but society also pays its fair share.
People with rheumatoid arthritis (RA) pay the price for living with their condition.
The heavy financial burdens that weigh on some people with RA range from lost wages to skyrocketing medical expenses.
There are also often the intangible factors such as a decrease in quality of life and an increase in stress levels.
If people with RA don’t have enough to worry about, new research suggests there is another price to pay. In addition to physical and emotional pain, people with RA cost the U.S. economy billions of dollars each year.
Arthritis is the leading cause of disability in the U.S., and people are often left unable to continue working. They are left with expensive medical bills, and the economy feels the strain.
The Full Costs of Rheumatoid Arthritis
There are 52.5 million adults with arthritis living in the U.S.
RA directly costs the U.S. about $19.3 billion a year (in 2005 dollars), according to an independent studyconducted by doctors and researchers in 2010. A third of that amount was given out to employers. Twenty-eight percent was given out to patients, and about 20 percent to caregivers and the government.
Added in with these costs are reduced quality of life, premature death, and total societal costs. That number reached $39.2 billion (in 2005 dollars).
The statistics from the U.S. Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) are even more staggering.
According to CDC estimates, the total costs from arthritis and related rheumatic conditions were about $128 billion in 2005. However, some estimates place the cost around $353 billion now. Some of these costs were for medical expenses and medical payouts, and the rest were from lost wages. These numbers are for all forms of arthritis, not just RA.
For RA, it is estimated that the overall cost of RA drugs is $41 billion ..
worldwide. That figure is projected to grow to $52 billion by 2018.
Lost wages is a significant problem among people with RA. On average, they must go on disability or stop working entirely within two years of disease onset and diagnosis.
The economic burden is notably worse for people with RA than it is for those with other forms of arthritis. People with RA are three times more likely to have a reduction in income. They are also often faced with more financial burdens due to high drug costs, out-of-pocket expenses.
The costs of RA medications have gone from about $50 per month to thousands of dollars per month in recent decades.
In fact, sales from RA drugs are the second highest class of pharmaceutical sales worldwide. The biologic class of RA drugs has grown about 45 percent in a five-year period.
It is predicted that medication costs will only continue to increase in coming years.
According to a recent study, from January 2013 to January 2016, the price of Enbrel rose 80 percent, the price of Humira rose 68 percent, and the price of Xeljanz rose 44 percent.
Biosimilars may offer new hope for people who live with RA. These drugs are similar to the more costly biologics, but they may be more affordable and more widely available. The U.S. Food and Drug Administration (FDA) recently approved the first biosimilar drug for RA, which is similar to Remicade...... Vin
- Forums
- ASX - By Stock
- MSB
- Rheumatoid Arthritis Costs are Astronomical
Rheumatoid Arthritis Costs are Astronomical
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online